Beer Institute Releases April 2022 Domestic Tax Paid Estimate

Published

3 months ago

May 25, 2022

WASHINGTON, May 25, 2022 (GLOBE NEWSWIRE) — Today, the Beer Institute published an unofficial estimate of domestic tax paid shipments by beer brewers for April 2022:

The April 2022 estimate is 13,700,000 barrels, a decrease of 5.9% compared to April 2021 removals of 14,557,000.

Domestic Tax Paid – TTB

(31 Gallon Barrels)

Month
2021
2022
Percent Change
Volume Change

January …

Full story available on Benzinga.com

Article: benzinga.com

Sex N’ the City: a (Super Unauthorized) Musical Parody Opens in Las Vegas

Published

3 months ago

May 25, 2022

PRNewswire

LAS VEGAS, May 25, 2022 /PRNewswire/ — The Modern Showrooms at Alexis Park Resort Hotel (www.ModernVegas.com) are ecstatic to announce everyone’s favorite New York City singles are making their way to Las Vegas in a live stage show Sex n’ The City: A (Super Unauthorized) Musical Parody. Sex n’ The City: A (Super Unauthorized) Musical Parody opens its first-ever residency beginning May 28, 2022. It’s the ultimate ‘Girls Night Out’ featuring Bottomless Champagne with most tickets.

Sex n’ The City: A (Super …

Full story available on Benzinga.com

Article: benzinga.com

Technology

Very Good Food Company Shares Skyrockets on Canada Retail Expansion

Published

3 months ago

May 25, 2022

Shivani Kumaresan

Very Good Food Company Inc (NASDAQ: VGFC) has increased retail distribution across Canada with Loblaw Companies Ltd (TSX: L) (OTC: LBLCF).
The company’s products will be available in more than 2,000 …

Full story available on Benzinga.com

Source Here: benzinga.com

Technology

Truist Sees 350% Upside on This Cancer-Focused Biopharma Stock – Read Why

Published

5 months ago

March 9, 2022

Vandana Singh

Truist has initiated coverage on Verastem Oncology Inc (NASDAQ: VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside.
Analyst Srikripa Devarakonda notes that trading at about 2-times cash, the stock is “undervalued” given its programs in two cancers.
Devarakonda adds that the Verastem base case is supported by a $470 million unadjusted U.S. opportunity in the ovarian cancer program, “early but strong” clinical data, and positive expert feedback.
Related:

Full story available on Benzinga.com

Article: benzinga.com